Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Michael Hejna"'
Autor:
Werner Dolak, Ildiko Mesteri, Reza Asari, Matthias Preusser, Barbara Tribl, Friedrich Wrba, Sebastian F. Schoppmann, Michael Hejna, Michael Trauner, Michael Häfner, Andreas Püspök
Publikováno v:
Endoscopy International Open, Vol 03, Iss 01, Pp E19-E28 (2015)
Background and study aims: Barrett’s esophagus (BE) – associated neoplasia can be treated endoscopically, but accurate assessment before intervention is challenging. This study aimed to investigate the role of confocal laser endomicroscopy (CLE)
Externí odkaz:
https://doaj.org/article/d1a92b6092d9492f848c73d23e319ceb
Autor:
Volker Wacheck, Oliver Langer, Markus Müller, Michael Hejna, Johannes Werzowa, Friedrich Wrba, Claudia Kuntner, Sabine Strommer, Doris Hoeflmayer, Agnes Jaeger-Lansky, Pamina Pflegerl, Thomas Wanek, Thorsten Fuereder
Purpose: In this study, we tested the antitumor activity of the dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor BEZ235 against gastric cancer in vitro and in vivo.Experimental Design: Gastric cancer cell lines (N87, MKN45, and MKN28) were incuba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091eb79f8603fa4f3af4c2836edee4eb
https://doi.org/10.1158/1078-0432.c.6519372.v1
https://doi.org/10.1158/1078-0432.c.6519372.v1
Autor:
Volker Wacheck, Oliver Langer, Markus Müller, Michael Hejna, Johannes Werzowa, Friedrich Wrba, Claudia Kuntner, Sabine Strommer, Doris Hoeflmayer, Agnes Jaeger-Lansky, Pamina Pflegerl, Thomas Wanek, Thorsten Fuereder
PDF file - 631K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4924b78ea2a8af9b93faa7d350a6eeaf
https://doi.org/10.1158/1078-0432.22442703.v1
https://doi.org/10.1158/1078-0432.22442703.v1
Autor:
Sebastian F. Schoppmann, Andrea Beer, Matthias Preusser, Werner Dolak, Peter Birner, Hossein Taghizadeh, Ahmed Ba-Ssalamah, Aysegül Ilhan-Mutlu, Michael Hejna
Publikováno v:
Cancer Biology & Therapy. 19:169-174
Attempts for identifying targeted therapy strategies in metastatic gastric and gastroesopheal junction cancer (upper-GI) revealed that the inhibition of human epidermal growth factor receptor-2 (HER2) by monoclonal antibody trastuzumab improves survi
Publikováno v:
Critical Reviews in Oncology/Hematology. 103:78-85
To our knowledge this is the first systemic review that provides an overview of the cutaneous paraneoplastic syndromes (CPS) (i.e., clinical manifestations, pathomechanisms, and treatment modalities) occurring in stomach cancer. CPS are caused by sub
Autor:
Robert Pirker, Leo Auerbach, Bernhard Parschalk, Sven Schneider, Christoph C. Zielinski, Heinz Gisslinger, Christine Marosi, Günther G. Steger, Michael Hejna, Gabriela Kornek, Sabine Zöchbauer-Müller, Wolfgang J. Köstler, Johannes Drach, Georg Goliasch, Martin Hülsmann, Stephanie Neuhold, Christopher Adlbrecht, Werner Scheithauer, Richard Pacher, Guido Strunk, Markus Raderer, Noemi Pavo
Publikováno v:
Heart. 101:1874-1880
Patients with cancer may display elevated levels of B-type natriuretic peptide (BNP) and high-sensitive troponin T (hsTnT) without clinical manifestation of cardiac disease. This study aimed to evaluate circulating cardiovascular hormones and hsTnT a
Autor:
Sonja, Kappel-Latif, Johannes, Zacherl, Michael, Hejna, Maria, Westerhoff, Dietmar, Tamandl, Ahmed, Ba-Ssalamah, Martina, Mittlböck, Brigitte, Wolf, Friedrich, Wrba, Irene, Kührer, Ursula, Pluschnig, Sebastian F, Schoppmann, Reinhold, Függer, Ronald, Zwrtek, Karl, Glaser, Josef, Karner, Friedrich, Längle, Etienne, Wenzl, Rudolf, Roka, Dietmar, Öfner, Jörg, Tschmelitsch, Michael, Hold, Felix, Keil, Michael, Gnant, Daniela, Kandioler, O, Dietze
Publikováno v:
European Surgery
Summary Background In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for
Autor:
Florian Huemer, Richard Greil, Hanno Ulmer, Ewald Wöll, Lukas Weiss, Josef Thaler, Wolfgang Eisterer, Vera Trommet, Michael Hejna, Felix Keil, Birgit Gruenberger, Michael A. Fridrik
Publikováno v:
Anticancer Research. 37
Background/aim Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acq
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients
Autor:
Richard Pacher, Noemi Pavo, Johannes Novak, Robert Pirker, Martin Hülsmann, Sabine Zöchbauer-Müller, Raphael Wurm, Guido Strunk, Anna Cho, Markus Raderer, Günther G. Steger, Leo Auerbach, Bernhard Parschalk, Michael Hejna, Barbara Kiesewetter, Werner Scheithauer, Sven Schneider, Christoph C. Zielinski, Heinz Gisslinger, Christine Marosi, Wolfgang J. Köstler, Georg Goliasch, Gabriela Kornek
Publikováno v:
Oncotarget
// Noemi Pavo 1 , Markus Raderer 2 , Georg Goliasch 1 , Raphael Wurm 1 , Guido Strunk 3 , Anna Cho 1 , Johannes F. Novak 1 , Heinz Gisslinger 2 , Gunther G. Steger 2 , Michael Hejna 2 , Wolfgang Kostler 2 , Sabine Zochbauer-Muller 2 , Christine Maros
Autor:
Reza Asari, Werner Dolak, Michael Hejna, Rainer Schmid, Christiane Thallinger, Sebastian F. Schoppmann, Nina Worel, Peter Birner, Markus Raderer, Matthias Preusser
Publikováno v:
Molecular and Clinical Oncology. 1:1079-1083
The assessment of the human epidermal growth factor receptor-2 (HER-2) status has become a routine diagnostic procedure for patients with advanced-stage gastroesophageal adenocarcinoma. The aim of this study was to evaluate the possible correlation b